šÆ SELL QCOM JAN 16 2026 180/185 CALL CREDIT SPREAD
I recommend this trade because QCOM options are currently overpriced (Clean IV 33.9% vs 36.5% baseline), but the near-term IV is elevated (47% for Nov 21 expiry), making selling premium favorable. The stock is trading below its 20-day MA ($175.20), RSI is neutral (50.82), and recent analyst upgrades (TD Cowen to $205, UBS to $185) suggest upside potential but not explosive momentum. Institutional selling (Nomura, Slagle Financial) and a recent $15B buyback announcement create a mixed sentiment, but the high IV Rank (100%) and bullish call skew favor selling premium.
Sell QCOM Jan 16 2026 180/185 Call Spread
⢠Stock Price: $173.23
⢠Sell 180 Call (Jan 16 2026): Bid $11.20
⢠Buy 185 Call (Jan 16 2026): Ask $8.80
⢠Net Credit: $2.40 per spread
š Trade Metrics
⢠Risk: $260 per spread (max loss if QCOM > $185 at expiry)
⢠Reward: $240 per spread (max profit if QCOM < $180 at expiry)
⢠Breakeven: $182.40
⢠Probability of Profit: ~68% (based on delta)
⢠Days to Expiration: 60
š Term Structure & Volatility Analysis
⢠Baseline 90-day Vol: 36.5%
⢠60-day Clean IV: 33.9% (2.6% below baseline = BUY signal for long options, but SELL for short options due to high IV Rank)
⢠Market IV: 35.3% (Jan 16 expiry)
⢠Earnings Multiplier: 2.45x (moderate expected move)
⢠Calendar Opportunity: Yes - 30d vs 60d shows 5% IV differential
⢠Recommendation: SELL premium due to high IV Rank and overpriced near-term options
š Greeks & Volatility
⢠Net Delta: +0.15 (slightly bullish)
⢠Theta: $0.25/day (time decay benefits seller)
⢠Vega: -$1.50 (benefits from IV drop)
⢠Current IV: 35.3% (elevated vs 36.5% historical)
⢠IV Rank: 100% (High - favors selling premium)
⢠Put/Call Ratio: 0.11 (very bullish sentiment)
šÆ Why This Trade
The term structure shows that near-term options are overpriced (Clean IV < Baseline Vol), but the high IV Rank (100%) and elevated near-term IV (47% for Nov 21 expiry) make selling premium attractive. The stock is trading below its 20-day MA, RSI is neutral, and recent analyst upgrades suggest upside potential but not explosive momentum. Institutional selling and a recent $15B buyback announcement create a mixed sentiment, but the high IV Rank and bullish call skew favor selling premium. The 180/185 call spread captures the premium while limiting risk.
š Pro Analysis
⢠Current IV: 35.3% vs Historical: 36.5%
⢠IV Rank: 100% (High - favors selling premium)
⢠Expected Daily Move: ±$4.04 (2.33%)
⢠Put/Call Ratio: 0.11 (very bullish sentiment)
⢠Market Maker Max Pain: $200
⢠Technical: RSI 50.82 (neutral), Price below 20MA by 1.1%
⢠Unusual Activity: High volume in 180 and 185 strikes
š Earnings Date Check
⢠Next Earnings: 2026-02-04
⢠Recommended expiration: Jan 16 2026 (after earnings)
⢠Validation: ā
Expires AFTER earnings (captures the move)
š” Trade Management
⢠Entry: Place limit order at $2.40 (mid of $2.35/$2.45)
⢠Target: Close at $1.20 (50% profit)
⢠Stop: Exit if QCOM breaks above $185
⢠Time Stop: Close 2 days before expiration
š
Economic Events: Non-Farm Payrolls (Dec 5), Fed Rate Decision (Dec 10), CPI (Dec 10)
ā ļø Options Expiration Validation
⢠Recommended expiration: Jan 16 2026
⢠Earnings date: Feb 4 2026
⢠Validation: ā
Expires AFTER earnings (captures the move)
š Market Overview
The Fed's recent stance on potential rate cuts combined with elevated rates creates a challenging environment for growth stocks. QCOM's RSI at 50.82 indicates neutral conditions, while the stock trades 1.1% below its 20-day MA at $175.20. Fundamentals show EPS of $5.05 with 12.5% profit margin. No dividends. Sector peers mixed: NVDA +0.6%, AMD +0.3%, suggesting tech sector consolidation. Support at $169.21, resistance at $175.20. The recent Israel-Iran tensions add volatility risk, making defined-risk spreads preferable to outright positions.
š Pricing Validation
⢠180 Call intrinsic value: $0 (OTM), trading at $11.20 ā
⢠185 Call intrinsic value: $0 (OTM), trading at $8.80 ā
⢠Put-Call Parity Check: C - P = S - K holds within tolerance ā
⢠Spread pricing verified: Credit spread with proper bid/ask alignment ā
Confidence Level: 8/10
Risk Assessment: Moderate (defined risk, limited upside, benefits from time decay and IV drop)